Description
The 2026 ADA Standards refine SGLT2 inhibitor use in CKD: clinicians may initiate therapy at an eGFR ≥20 mL/min/1.73 m² and continue it as kidney function declines, and simultaneous initiation of an SGLT2 inhibitor plus the nonsteroidal MRA finerenone can be considered in adults with type 2 diabetes, UACR ≥100 mg/g, and eGFR 30–90 mL/min/1.73 m² on maximal RAS blockade. This proactive, front‑loaded strategy—supported by the CONFIDENCE study showing ~52% greater UACR reduction with the combination versus monotherapy—aims to maximize albuminuria reduction during high‑risk intervals and translate to long‑term nephroprotection. KDIGO draft guidance and CKM recommendations align with these thresholds, simplifying clinical decision‑making. Clinicians should still individualize care, monitor potassium and renal function, and consider drug interactions and tolerability, but the converging guidelines strengthen the case for early, combined renoprotective therapy in albuminuric type 2 diabetes.